ALLK Dec 2024 0.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:12PM EDT. Market open.
| Previous close | 1.0500 |
| Open | 1.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 0.50 |
| Expiry date | 2024-12-20 |
| Day's range | 1.0000 - 1.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 24 |
- GuruFocus.com
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
Detailed Analysis of Financial Performance and Future Outlook
GlobeNewswireAllakos Provides Business Update and Reports First Quarter 2024 Financial Results
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and multiple ascending dose (MAD) cohorts of the randomized, double-blind, placebo-controlled
Simply Wall St.With 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional owners
Key Insights Institutions' substantial holdings in Allakos implies that they have significant influence over the...
© 2024 Yahoo. All rights reserved.